Hepion Pharmaceuticals (FRA:336) Total Assets : €14.71 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Hepion Pharmaceuticals Total Assets?

Hepion Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was €14.71 Mil.

During the past 12 months, Hepion Pharmaceuticals's average Total Assets Growth Rate was -55.70% per year. During the past 3 years, the average Total Assets Growth Rate was -25.20% per year. During the past 5 years, the average Total Assets Growth Rate was -3.00% per year.

During the past 11 years, Hepion Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 209.10%. The lowest was -25.20%. And the median was 13.60%.

Total Assets is connected with ROA %. Hepion Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 was -67.11%. Total Assets is also linked to Revenue through Asset Turnover. Hepion Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Hepion Pharmaceuticals Total Assets Historical Data

The historical data trend for Hepion Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hepion Pharmaceuticals Total Assets Chart

Hepion Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

18.55

39.99

91.64

56.87

16.59

Hepion Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															46.23	33.69	23.43	16.59	14.71

Hepion Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Hepion Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	6.677	+	9.916
	=	16.59

Hepion Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	6.919	+	7.791
	=	14.71

Hepion Pharmaceuticals (FRA:336) Total Assets Explanation

Total Assets is connected with ROA %.

Hepion Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-10.504	/	( (16.592	+	14.71)	/ 2 )
	=	-10.504	/	15.651
	=	-67.11 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Hepion Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (16.592	+	14.71)	/ 2 )
=	0	/	15.651
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Hepion Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Hepion Pharmaceuticals (FRA:336) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (FRA:336) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

HEPA:USA

Address

399 Thornall Street, First Floor, Edison, NJ, USA, 08837

Website

https://www.hepionpharma.com

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Hepion Pharmaceuticals (FRA:336) Headlines

No Headlines